Trump Taps Dr. Oz as Lead Negotiator for ‘Most Favored Nation’ Drug Pricing Policy

President Donald Trump has unofficially asked Dr. Mehmet Oz, the administrator of the Centers for Medicare and Medicaid Services (CMS), to lead negotiations with drugmakers as part of the administration's 'Most Favored Nation' (MFN) drug pricing policy initiative1 2.

Trump referred to Oz as a 'very tough hombre' and tasked him with bringing down drug costs substantially, emphasizing his confidence that Oz could achieve significant price reductions quickly2.

The MFN policy aims to set U.S. drug prices at levels comparable to those in countries where the same drugs are sold for less, targeting high-cost medications that lack generic or biosimilar competition5.

Recent statements by U.S. Customs and Border Protection (CBP) have warned pharmaceutical companies about ensuring proper import/export documentation, specifically referencing the MFN policy and cautioning against trade evasion practices that might arise in response to new tariffs or regulations2.

Dr. Oz has been publicly discussing the administration’s efforts to lower prescription drug prices through policy changes, including equalizing U.S. drug costs with those in other nations3 4.